Press Release

amcure to present data on the mode of action of its lead compound AMC303 at the AACR Annual Meeting 2019

Eggenstein-Leopoldshafen, Germany – 28 March 2019: amcure, a biopharmaceutical company developing first-in-class cancer therapeutics, will present a poster on the mode of action of its lead candidate AMC303 at the upcoming American Association for Cancer Research (AACR) Annual Meeting. The first-in-class drug candidate AMC303, which is currently undergoing a Phase Ib clinical trial, targets CD44v6 to inhibit tumor growth and metastasis in epithelial tumors by blocking several relevant tyrosine kinase pathways.

AACR Annual Meeting 2019
Date: 29 March – 3 April 2019
Venue: Georgia World Congress Center, Atlanta, Georgia, USA

Title: AMC303 inhibits tumor growth and metastasis in animal models by targeting CD44v6, a co-receptor of multiple oncogenic receptor tyrosine kinases
Session: Targeted Therapies and Immunological/Tumor Microenvironment Effects
Abstract number: 4855, Section 15
Speaker: Martin Augsten, Senior Research Scientist, amcure
Time: 3 April 2019, 8:00 AM - 12:00 PM

amcure will present results of its preclinical studies demonstrating the unique mode of action of AMC303. *In vitro* studies demonstrate that AMC303 specifically attenuates the oncogenic signaling of three CD44v6-dependent receptor tyrosine kinases, namely c-MET, VEGFR2 and RON. In addition, they will show results from a tumor mouse model demonstrating a marked attenuation of tumor growth and metastasis and a significant increase in survival by treatment with AMC303. Treated tumors displayed increased apoptosis and necrosis along with a reduction in myofibroblast infiltration, angiogenesis and vessel permeability. The full abstract is available online via the AACR website:
https://www.abstractsonline.com/pp8/#!/6812/presentation/7891

About AMC303
amcure's lead compound, AMC303, is being developed as a potential treatment for patients with advanced and metastatic epithelial tumors, e.g. pancreatic cancer, head and neck cancer, gastric cancer, colorectal cancer, breast cancer and lung cancer. AMC303 has a high specificity for inhibiting CD44v6, a co-receptor required for signaling through multiple cellular pathways (c-Met, VEGFR-2, RON) involved in tumor growth, angiogenesis and the development and regression of metastases. AMC303 has demonstrated strong effects in various *in vitro* and *in vivo* assays.

About amcure
amcure GmbH is a spin-off from the Karlsruhe Institute of Technology established in 2012. The company develops peptide-based compounds for the treatment of highly metastatic forms of cancer. amcure's most advanced development candidate, AMC303, has entered clinical development and has demonstrated in *in vivo* animal proof-of-concept studies a high efficacy against different types of epithelial cancers. amcure is supported by a grant from the German Federal Ministry of Education and Research.

Contact
amcure GmbH
Dr. Klaus Dembowsky, CEO
Hermann-von Helmholtz-Platz 1
76344 Eggenstein-Leopoldshafen, Germany
Phone: +49 (0) 7247 934249-4 or +49 (0) 171 7930077
Fax: +49 (0) 7247 934249-9
E-Mail: info[at]amcure.com
Internet: www.amcure.com

Media contact
MC Services AG
Julia von Hummel
Tel.: +49 (0) 89 210 228-34
Mobil: +49 (0) 1719779192
E-Mail: Julia.vonhummel[at]mc-services.eu

SPONSORED BY THE
Federal Ministry of Education and Research